Mortality (within 30 days of discharge) · women with gynaecological cancers
It is very uncertain whether enhanced recovery after surgery programme changes mortality (within 30 days of discharge) compared with traditional care (very low certainty).
1 finding from 1 review
Patient readmissions · women with gynaecological cancers
Enhanced recovery after surgery programme may leads to lower readmission (within 30 days of operation) compared with traditional care (low certainty).
1 finding from 1 review
Time from completion of operation to first flatus (hours) · women with gynaecological cancers
1 finding from 1 review
Time from completion of operation to first bowel movement (hours) · women with gynaecological cancers
1 finding from 1 review
Participant satisfaction · women with gynaecological cancers
1 finding from 1 review
Economic outcomes · women with gynaecological cancers
1 finding from 1 review
Overall survival · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes overall survival compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Overall survival · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel showed no clear difference in overall survival compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Response rate · women with recurrent epithelial ovarian cancer
It is very uncertain whether 175 mg/m2 paclitaxel changes response rate compared with 250 mg/m2 paclitaxel (very low certainty).
1 finding from 1 review
Response rate ‐ platinum‐sensitive · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel may leads to lower response rate ‐ platinum‐sensitive compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Response rate ‐ platinum‐resistant · women with recurrent epithelial ovarian cancer
It is very uncertain whether 175 mg/m2 paclitaxel changes response rate ‐ platinum‐resistant compared with 250 mg/m2 paclitaxel (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Neurotoxicity · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel probably leads to lower neurotoxicity compared with 250 mg/m2 paclitaxel (moderate certainty).
1 finding from 1 review
Neutropenia · women with recurrent epithelial ovarian cancer
175 mg/m2 paclitaxel showed no clear difference in neutropenia compared with 250 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Alopecia ‐ not reported · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · women with recurrent epithelial ovarian cancer
135 mg/m2 paclitaxel showed no clear difference in overall survival compared with 175 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Response rate · women with recurrent epithelial ovarian cancer
It is very uncertain whether weekly paclitaxel changes response rate compared with three‐weekly paclitaxel (very low certainty).
1 finding from 1 review
Response rate · women with recurrent epithelial ovarian cancer
135 mg/m2 paclitaxel showed no clear difference in response rate compared with 175 mg/m2 paclitaxel (low certainty).
1 finding from 1 review
Quality of life ‐ not measured · women with recurrent epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found